Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1

Yao, Xuan; Deng, Xueqiang; Zhao, Yanzhi; Deng, Binbin; Deng, Jianyong; Huang, Fan; Du, Yunyan; Hao, Lu

doi:10.1016/j.yexcr.2019.111804

Cited by 23 publications

(33 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, miR-375 increases the activity of YAP1, while miR-624-5p (which is overexpressed in OS) induces cell proliferation, migration, and invasion by increasing the amount of nuclear YAP [101,102]. Furthermore, a recent study has reported that FAT10, a ubiquitin-like protein, stabilizes YAP expression by regulating its ubiquitination and degradation [103].…”

Section: Osteosarcomamentioning

confidence: 99%

Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?

Morice

Danieau

Rédini

et al. 2020

Cancers

View full text Add to dashboard Cite

Osteosarcoma and Ewing sarcoma are the most prevalent bone pediatric tumors. Despite intensive basic and medical research studies to discover new therapeutics and to improve current treatments, almost 40% of osteosarcoma and Ewing sarcoma patients succumb to the disease. Patients with poor prognosis are related to either the presence of metastases at diagnosis or resistance to chemotherapy. Over the past ten years, considerable interest for the Hippo/YAP signaling pathway has taken place within the cancer research community. This signaling pathway operates at different steps of tumor progression: Primary tumor growth, angiogenesis, epithelial to mesenchymal transition, and metastatic dissemination. This review discusses the current knowledge about the involvement of the Hippo signaling pathway in cancer and specifically in paediatric bone sarcoma progression.

show abstract

Section: Osteosarcomamentioning

confidence: 99%

Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?

Morice

Danieau

Rédini

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…For example, YAP1 knockdown inhibited OS cell proliferation in vitro and in vivo. [19][20][21][22] In addition, upregulation of YAP1 promoted OS cell proliferation, migration, and invasion, thereby leading to tumorigenesis. 23 TRPS1 is also generally overexpressed in multiple types of cancer [11][12][13]24,25 and our previous study has confirmed its role in enhancing drug resistance in OS cells.…”

Section: Discussionmentioning

confidence: 99%

<p>TRPS1 and YAP1 Regulate Cell Proliferation and Drug Resistance of Osteosarcoma via Competitively Binding to the Target of circTADA2A – miR-129-5p</p>

Zhang¹,

Ji²,

Zhou³

et al. 2020

OTT

View full text Add to dashboard Cite

Introduction: The yes-associated protein (YAP) and trichorhinophalangeal syndrome 1 (TRPS1) have been reported to account for the pathogenesis of cancers and may play an important role in osteosarcoma (OS). This study intended to investigate the modulatory effect and relationship of TRPS1 and YAP1 in OS cells. Methods: The expression difference of YAP1 and TRPS1 in OS cells was measured. Then, the effect of circTADA2A silence on YAP1 and TRPS1 expression as well as OS proliferation and drug resistance was estimated. Results: TRPS1 and YAP1 were upregulated in OS cell lines, and TRPS1 and YAP1 were highly expressed in MG63 and U2OS cells, respectively. The cell proliferation of MG63 was lower than that of U2OS, but the opposite result was observed in the presence of cisplatin (DDP). CircTADA2A was upregulated while miR-129-5p was downregulated in MG63 and U2OS cells compared. Besides, circTADA2A knockdown inhibited cell proliferation and reduced DDP resistance in both MG63 and U2OS. MiR-129-5p was increased but TRPS1 and YAP1 were decreased by circTADA2A knockdown. Meanwhile, circTADA2A knockdown reduced TRPS1 protein expression but enhanced phosphorylated (p)-YAP1. In xenograft OS tumor mice, circTADA2A knockdown inhibited tumor growth in the absence or presence of DDP. Finally, miR-129-5p could bind to circTADA2A, TRPS1 and YAPS. Discussion: CircRNA TADA2A could target miR-129-5p, which was competitively bound by TRPS1 and YAP1, thereby regulating OS cell proliferation and drug resistance.

show abstract

“…It has been suggested that FAT10 can stabilise YAP protein through regulation of its ubiquitination and proteasome-mediated degradation. Therefore, FAT10 can be considered as a potential marker for OS (Yi et al, 2020). It has been suggested that dysregulation of this enzyme may be associated with many human cancers, such as breast and colorectal cancer (Y.…”

Section: Involvement Of the Hippo Pathway In Osmentioning

confidence: 99%

“…HLA‐F adjacent transcript 10 (FAT10) is a member of the ubiquitin‐like protein family and is also known as ubiquitin D (Xiang et al, 2019). Studies have shown that FAT10 may arrest the cell cycle at the G1‐phase and lead to inhibition of apoptosis (Yi et al, 2020). According to the same studies, FAT10 protein is highly expressed in OS tissues and cells.…”

Section: Involvement Of the Hippo Pathway In Osmentioning

confidence: 99%

See 1 more Smart Citation

The Hippo in the room: Targeting the Hippo signalling pathway for osteosarcoma therapies

Rothzerg

Ingley

Mullin

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Osteosarcoma (OS) is a primary malignant bone tumour which usually occurs in children and adolescents. OS is primarily a result of chromosomal aberrations, a combination of acquired genetic changes and, hereditary, resulting in the dysregulation of cellular functions. The Hippo signalling pathway regulates cell and tissue growth by modulating cell proliferation, differentiation, and migration in developing organs. Mammalian STE20-like 1/2 (MST1/2) protein kinases are activated by neurofibromatosis type 2, Ras association domain family member 2, kidney and brain protein, or other factors. Interactions between MST1/2 and salvador family WW domain-containing protein 1 activate large tumour suppressor kinase 1/2 proteins, which in turn phosphorylate the downstream Yes-associated protein 1/transcriptional coactivator with PDZ-binding motif (YAP/TAZ). Moreover, dysregulation of this pathway can lead to aberrant cell growth, resulting in tumorigenesis. Interestingly, small molecules targeting the Hippo signalling pathways, through affecting YAP/TAZ cellular localisation and their interaction with members of the TEA/ATTS domain family of transcriptional enhancers are being developed and hold promise for the treatment of OS. This review discusses the existing knowledge about the involvement of the Hippo signalling cascade in OS and highlights several small molecule inhibitors as potential novel therapeutics.

show abstract

Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1

Cited by 23 publications

References 34 publications

Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?

Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?

<p>TRPS1 and YAP1 Regulate Cell Proliferation and Drug Resistance of Osteosarcoma via Competitively Binding to the Target of circTADA2A – miR-129-5p</p>

The Hippo in the room: Targeting the Hippo signalling pathway for osteosarcoma therapies

Contact Info

Product

Resources

About